Home > Insider Trading > Filing (0000899243-18-009413)

Filing Details

Accession Number:: 0000899243-18-009413
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-04-04 13:33:53
Reporting Period:: 2018-04-02

Accepted Time:: 2018-04-04 13:33:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661998	Homology Medicines Inc.	FIXX	()	0331

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1021944	Ltd (Private) Holdings Temasek	60B Orchard Road #06-18 Tower 2, The Atrium@Orchard Singapore U0 238891	No	No	Yes	No
1379348	Ltd Pte Management Fullerton	60B Orchard Road #06-18 Tower 2, The Atrium@Orchard Singapore U0 238891	No	No	Yes	No
1379349	Ltd Private Sciences Life Temasek	60B Orchard Road #06-18 Tower 2, The Atrium@Orchard Singapore U0 238891	No	No	Yes	No
1379350	Ltd Pte Investments V-Sciences	60B Orchard Road #06-18 Tower 2, The Atrium@Orchard Singapore U0 238891	No	No	Yes	No
1673754	Ltd. Pte. Beta Tls	60B Orchard Road #06-18 Tower 2, The Atrium@Orchard Singapore U0 238891	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-04-02	1,605,681	$0.00	1,605,681	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-04-02	989,612	$0.00	2,595,293	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-04-02	625,000	$16.00	3,220,293	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-04-02	1,605,681	$0.00	1,605,681	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-04-02	989,612	$0.00	989,612	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.
The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.
Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.
Consists of 989,612 shares of Common Stock held of record by TLS Beta.
Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.
TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.